Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Regeneron Pharmaceuticals Inc. (NASDAQ ... in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented at the 2025 ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) on Saturday presented ...

Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...